Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

World Hepatitis Association

- PMLiVE

WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

The prequalification confirms the treatment meets WHO’s standards for quality, effectiveness and safety

- PMLiVE

Omicron prompts global action

A new variant of concern discovered in southern Africa is quickly spreading around the world, prompting government to take action

- PMLiVE

Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic

Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’...

Avalere Health

- PMLiVE

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

Roche's Actemra and Sanofi's Kevzara are included in WHO's updated patient care guidelines

- PMLiVE

Sinovac’s COVID-19 vaccine receives WHO emergency use listing

Vaccine found to be 51% effective in preventing symptomatic disease, meeting the WHO's recommendation of at least 50% efficacy

- PMLiVE

China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine

WHO said decision gives the 'green light' for the vaccine to be rolled out globally

- PMLiVE

WHO to review Moderna’s COVID-19 vaccine for emergency use listing this week

WHO is also due to review vaccines from Sinopharm and Sinovac for possible EUAs

- PMLiVE

WHO director-general says pandemic can be brought under control within months

World has tools to curb pandemic if applied ‘consistently and equitably’

- PMLiVE

WHO backs emergency use of J&J’s one-dose COVID-19 vaccine

Vaccine is already approved for emergency use by the European Commission and the FDA

- PMLiVE

J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing

In phase 3, J&J's vaccine was 66% effective overall at preventing moderate-to-severe COVID-19

- PMLiVE

WHO agrees to no-fault compensation for rare serious side effects from COVAX-distributed vaccines

The no-fault compensation fund will be accessible via a web portal by 31 March 2021

- PMLiVE

WHO grants emergency use listing for AZ/Oxford University’s COVID-19 vaccine

The emergency use listing authorises the use of the vaccine in all adults, including over-65s

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links